Osaka Saiseikai Suita Hospital
Osaka Saiseikai Suita Hospital
Suda N.,Osaka Saiseikai Noe Hospital |
Kamiya H.,Osaka Saiseikai Noe Hospital |
Koie M.,Osaka Saiseikai Noe Hospital |
Santou T.,Osaka Saiseikai Noe Hospital |
And 11 more authors.
Journal of the Japan Diabetes Society | Year: 2015
The Department of Diabetic Dialysis Prevention Guidance Management has been newly established and early active team intervention is being implemented with the aim of preventing the shift to dialysis treatment in diabetic patients. We conducted two surveys of Saiseikai hospitals throughout in Japan regarding the current status after introducing diabetic dialysis prevention guidance and investigated potential future issues. The most common reason for team intervention not being implemented at the facilities was the inability to secure staff members. Teams were primarily composed of physicians, nurses, and dietitians, and certified diabetes educators were included in the team at 91 % of the hospitals. Having nurses and dietitians offer guidance at the same site was believed to lead to shared patient information and unified guidance content among medical professionals, thereby leading to a reduced guidance time. Although the responses indicated that the effects of guidance were felt at over 80 % of the facilities, the proportion of nurses and dietitians who responded that they had some misgivings about the guidance increased in the second survey, and 62 % of the teams overall felt that the guidance activities were burdensome. These issues therefore must be improved in the future.
Narazaki H.,University of Hyogo |
Ishizaki J.,Osaka Saiseikai Suita Hospital |
Inada H.,University of Hyogo |
Tani S.,Japan National Cardiovascular Center Research Institute |
And 2 more authors.
6th International Conference on Soft Computing and Intelligent Systems, and 13th International Symposium on Advanced Intelligence Systems, SCIS/ISIS 2012 | Year: 2012
Recently, the number of patients with diabetes mellitus (DM) has been increasing. Because DM causes many complications, it is important for patients with DM to control their blood sugar levels. However, there is not an effective method for the patients to manage their blood sugar levels at home. Therefore, we developed a home support system for the patients by which the patient can accumulate various biological measured data and send the data to a medical institution. At the institution, a physician can check the data and provide instructions via e-mail to the patient at home. The system is composed of a smartphone used by the patient, a server installed at the medical institution and a personal computer (PC) used by the physician. The patient measures data such as weight, blood pressure, blood sugar, etc. at home and send these data to the server using the smartphone. The physician can check the patient data, including a medical and medication history, and provide instructions via e-mail to the patient using the PC. For our purpose, an Android smartphone was selected as a terminal, and the system was created using XML so that the data could be read with a web browser in any environment. We anticipate our developed system will be useful to support patients with DM at home. © 2012 IEEE.
Minagawa Y.,Tottori Prefectural Central Hospital |
Shimada M.,Tottori University |
Itamochi H.,Tottori University |
Sato S.,Tottori University |
And 3 more authors.
Gynecologic and Obstetric Investigation | Year: 2012
Aim: To evaluate the feasibility of biweekly paclitaxel treatment as maintenance chemotherapy for patients with advanced müllerian carcinoma. Methods: Thirty patients with stage III or IV ovarian, fallopian tube, and peritoneal cancers who underwent primary optimal surgery and standard 6 cycles of carboplatin/taxane-based chemotherapy and exhibited a complete clinical response were entered in this study. Paclitaxel 80 mg/m 2 was administered biweekly for 12 cycles. Patients were evaluated monthly for treatment-related toxicity. Results: Four patients, including 3 disease progressions and 1 bone marrow suppression, came off the protocol therapy. Twenty-six (86.7%) patients received complete treatment. Although the major toxicity was neutropenia, most of those patients (27/30, 90.0%) did not experience grade 3 or 4 neutropenia. Twenty-four (80.0%) patients showed persistent grade 1 neuropathy and the remaining 6 (20.0%) did not as a result of prior therapy. However, none experienced neuropathy progression during or after the protocol therapy. Most (17/22, 77.3%) of the completely treated patients experienced a regression of symptoms during and after therapy. Conclusion: Biweekly paclitaxel therapy is well tolerated by patients with advanced müllerian carcinoma and is therefore acceptable as a candidate for maintenance chemotherapy in these patients. Copyright © 2012 S. Karger AG.